Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Market Cap:2400M; Shares Outstanding:63.9M; Short Interest: 11.77%; Q3 2019(9/30/19): Cash 434M. Loss 69M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 144，no change
Shares hold: 42026.3k shares. no change
shares% hold: 65.78%，no change
2020.01.08: Apellis Pharma prices stock offering at $37k